TPEx方案对比EXTREME方案一线治疗复发或转移性头颈鳞癌的随机II期试验
这项多中心、开放标签、随机II期试验在法国、西班牙和德国68个中心纳入541例复发或转移性头颈鳞癌患者,比较TPEx方案(多西他赛-铂-西妥昔单抗)与标准EXTREME方案(铂-氟尿嘧啶-西妥昔单抗)的疗效与安全性。TPEx可作为不适合 upfront 帕博利珠单抗患者的替代选择。
要点
- TPEx组≥3级不良事件发生率81%,显著低于EXTREME组的93%。
- TPEx方案可考虑用于不适合 upfront 帕博利珠单抗的复发/转移性HNSCC患者。
核心结论
- TPEx方案对比EXTREME方案未显著改善总生存,但安全性更优,可作为替代选择。
研究设计与样本
- 多中心、开放标签、随机II期试验,在法国、西班牙和德国68个中心进行。
- 纳入541例18-70岁、ECOG评分≤1的复发或转移性头颈鳞癌患者,按1:1随机分配至TPEx组(271例)或EXTREME组(270例)。
主要发现
- TPEx组严重不良事件发生率45%(118/263),EXTREME组54%(143/265)。
关键数值与推荐
- TPEx方案:多西他赛75 mg/m2和顺铂75 mg/m2第1天静脉给药,西妥昔单抗第1、8、15天给药(第1周期第1天400 mg/m2,后续每周250 mg/m2),每21天重复,共4周期,每周期系统给予G-CSF支持;疾病控制后西妥昔单抗500 mg/m2每2周维持治疗。
- EXTREME方案:氟尿嘧啶4000 mg/m2第1-4天,顺铂100 mg/m2第1天,西妥昔单抗第1、8、15天给药(第1周期第1天400 mg/m2,后续每周250 mg/m2),每21天重复,共6周期,疾病控制后每周西妥昔单抗250 mg/m2维持治疗;G-CSF支持非强制。
临床怎么用
- 对于复发或转移性HNSCC一线治疗,TPEx方案可作为EXTREME方案的替代选择,尤其适用于不适合 upfront 帕博利珠单抗的患者。
- TPEx方案需每周期系统给予G-CSF支持,以降低不良事件风险。
局限性
- 本研究为II期试验,主要终点未达到统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel-platinum-cetuximab) showed promising results, with a median overall survival of 14·0 months in first-line recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). We therefore aimed to compare the efficacy and safety of the TPEx regimen with the standard of care EXTREME regimen (platinum-fluorouracil-cetuximab) in this setting. METHODS: This was a multicentre, open-label, randomised, phase 2 trial, done in 68 centres (cancer centres, university and general hospitals, and private clinics) in France, Spain, and Germany. Eligible patients were aged 18-70 years with histologically confirmed recurrent or metastatic HNSCC unsuitable for curative treatment; had at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1; and had an Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less. Participants were randomly assigned (1:1) using the TenAlea website by investigators or delegated clinical research associates to the TPEx regimen or the EXTREME regimen, with minimisation by ECOG performance status, type of disease evolution, previous cetuximab treatment, and country. The TPEx regimen consisted of docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both intravenously on day 1, and cetuximab on days 1, 8, and 15 (intravenously 400 mg/m2 on day 1 of cycle 1 and 250 mg/m2 weekly subsequently). Four cycles were repeated every 21 days with systematic granulocyte colony-stimulating factor (G-CSF) support at each cycle. In case of disease control after four cycles, intravenous cetuximab 500 mg/m2 was continued every 2 weeks as maintenance therapy until progression or unacceptable toxicity. The EXTREME regimen consisted of fluorouracil 4000 mg/m2 on day 1-4, cisplatin 100 mg/m2 on day 1, and cetuximab on days 1, 8, and 15 (400 mg/m2 on day 1 of cycle 1 and 250 mg/m2 weekly subsequently) all delivered intravenously. Six cycles were delivered every 21 days followed by weekly 250 mg/m2 cetuximab as maintenance therapy in case of disease control. G-CSF support was not mandatory per the protocol in the EXTREME regimen. The primary endpoint was overall survival in the intention-to-treat population; safety was analysed in all patients who received at least one dose of chemotherapy or cetuximab. Enrolment is closed and this is the final analysis. This study is registered at ClinicalTrials.gov, NCT02268695. FINDINGS: Between Oct 10, 2014, and Nov 29, 2017, 541 patients were enrolled and randomly assigned to the two treatment regimens (271 to TPEx, 270 to EXTREME). Two patients in the TPEx group had major deviations in consent forms and were not included in the final analysis. Median follow-up was 34·4 months (IQR 26·6-44·8) in the TPEx group and 30·2 months (25·5-45·3) in the EXTREME group. At data cutoff, 209 patients had died in the TPEx group and 218 had died in the EXTREME group. Overall survival did not differ significantly between the groups (median 14·5 months [95% CI 12·5-15·7] in the TPEx group and 13·4 months [12·2-15·4] in the EXTREME group; hazard ratio 0·89 [95% CI 0·74-1·08]; p=0·23). 214 (81%) of 263 patients in the TPEx group versus 246 (93%) of 265 patients in the EXTREME group had grade 3 or worse adverse events during chemotherapy (p<0·0001). In the TPEx group, 118 (45%) of 263 patients had at least one serious adverse event versus 143 (54%) of 265 patients in the EXTREME group. 16 patients in the TPEx group and 21 in the EXTREME group died in association with adverse events, including seven patients in each group who had fatal infections (including febrile neutropenia). Eight deaths in the TPEx group and 11 deaths in the EXTREME group were assessed as treatment related, most frequently sepsis or septic shock (four in each treatment group). INTERPRETATION: Although the trial did not meet its primary endpoint, with no significant improvement in overall survival with TPEx versus EXTREME, the TPEx regimen had a favourable safety profile. The TPEx regimen could provide an alternative to standard of care with the EXTREME regimen in the first-line treatment of patients with recurrent or metastatic HNSCC, especially for those who might not be good candidates for up-front pembrolizumab treatment. FUNDING: Merck Santé and Chugai Pharma.
引用
- Guigay J, Aupérin A, Fayette J, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021. PMID: 33684370. doi:10.1016/S1470-2045(20)30755-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。